EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cerebrospinal fluid HOXB3 does not differentiate relapsing–remitting multiple sclerosis from idiopathic intracranial hypertension: a pilot study

Firdevs Uluc, Fatma Bilgili, Nevin Horasan, Sule Aydin Turkoglu

Northwestern Medical Journal · 10.04.2026 · 6 (2) · 167-173

DOI: 10.54307/nwmj.2026.211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Northwestern Medical Journal, online erschienen am 10.04.2026. Verfasst von Firdevs Uluc und 3 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Multiple sclerosis (MS) is a complex disease in terms of diagnosis and differential diagnosis due to the variety of clinical and radiological findings. Many diseases have similar characteristics and mimic MS. Thus, potential differential biomarkers have an importance for diagnosis of MS. Homeobox protein-3 (HOXB3) is a homeobox transcription factor implicated in immune cell regulation and neurodevelopment, and recent cerebrospinal fluid proteomic studies have suggested its potential role in neuroinflammatory processes, making it a plausible candidate biomarker for differential diagnosis in MS. The aim of this study was to investigate whether cerebrospinal fluid levels of HOXB3 differ between treatment-naïve patients with relapsing–remitting multiple sclerosis (RRMS) during relapse and patients with idiopathic intracranial hypertension (IIH).

Methods

Forty-one pwMS diagnosed with McDonald criteria were enrolled for the case groups. Thirty-four patients with IIH diagnosed with Dandy criteria were enrolled for control group. We measured cerebrospinal fluid level of HOXB3 (CSF HOXB3) by Enzyme-Linked Immunosorbent Assay (ELISA) method.

Results

No significant difference was observed in CSF HOXB3 levels between pwMS and control group. The ROC curve for HOXB3 was not statistically significant with the AUC at 0.573.

Conclusion

HOXB3 does not differentiate RRMS from IIH under the studied conditions.

Zitieren

APA

Uluc, F., Bilgili, F., Horasan, N., & Turkoglu, S. A. (2026). Cerebrospinal fluid HOXB3 does not differentiate relapsing–remitting multiple sclerosis from idiopathic intracranial hypertension: a pilot study. Northwestern Medical Journal, 6(2), 167-173. https://doi.org/10.54307/nwmj.2026.211

Vancouver

Uluc F, Bilgili F, Horasan N, Turkoglu SA. Cerebrospinal fluid HOXB3 does not differentiate relapsing–remitting multiple sclerosis from idiopathic intracranial hypertension: a pilot study. Northwestern Medical Journal. 2026;6(2):167-173. doi:10.54307/nwmj.2026.211

BibTeX
@article{Uluc2026,
  author = {Uluc, Firdevs and Bilgili, Fatma and Horasan, Nevin and Turkoglu, Sule Aydin},
  title = {Cerebrospinal fluid HOXB3 does not differentiate relapsing–remitting multiple sclerosis from idiopathic intracranial hypertension: a pilot study},
  journal = {Northwestern Medical Journal},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {167--173},
  doi = {10.54307/nwmj.2026.211}
}
Kostenlos starten →